The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study
Funder
National Health and Medical Research Council
Funding Amount
$1,010,141.00
Summary
The purpose of this research study is to determine whether administering radiotherapy to melanoma brain tumours, in combination with 2 drugs called nivolumab and ipilimumab(also known as Immunotherapy), will be more effective than treating brain tumours with immunotherapy. Patients in this trial will be randomly assigned to 1 of 2 treatment groups. Group 1 will receive radiotherapy to their melanoma brain lesion(s), combined with immunotherapy. Group 2 will receive immunotherapy treatment alone.
Breathing Control As A Treatment For Non-Epileptic Seizures
Funder
National Health and Medical Research Council
Funding Amount
$1,740,186.00
Summary
Non-epileptic Seizures (NES) are fits that look like epilepsy but are not, and are instead thought to be a psychological response to problems. Treating them psychologically is difficult, however, and doesn't usually work. We have discovered that patients' fits involve hyperventilation, like a panic attack, and can be stopped by teaching them to control their breathing in a similar way. In this study we aim to prove this, by completing a trial of breath control training in NES.
This clinical trial will test whether a combination of two safe therapies, abatacept and nasal insulin, can stop the immune attack that causes type 1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1 diabetes will receive either abatacept and nasal insulin or abatacept and nasal placebo for one year to determine if combined immune therapy preserves pancreas function and decreases the need for insulin therapy.